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Objectives: At present there are several drugs for the treatment of advanced renal cell 
carcinoma (ARCC). The main objective of this work was to perform a systematic review 
(SR) and meta-analysis (MA) of clinical randomized studies that compared target cell 
therapies (TCT).
Materials and Methods: SR identified clinical randomized trials that compared TCT versus 
interferon-alpha in the treatment of patients with ARCC. In order to analyze efficiency, it 
was evaluated free-survival progression (FSP), total survival (TS) and response rate (RR).
Results: In relation to first line treatment, seven studies of TCT were identified using suni-
tinib, sorafenib, bevacizumab and temsirolimus; and two studies with  sorafenib and eve-
rolimus for second line treatment. Relative risk (RRi) of MA for FSP of first line therapies 
was: 0.83, CI = 0.78-0.87, I2 = 94% and p < 0.00001. Best results of RR of specific FSP 
among studies were: 0.38, sunitinib, CI = 0.25-0.58, bevacizumab, 0.62, CI = 0.47-0.83; 
and temsirolimus, 0.78, CI = 0.70-0.87. MA didn’t show any benefit regarding TS of first 
line treatment of all analyzed drugs. As for RR significant results were: sunitinib, 3.83 
CI = 2.86-5.12; bevacizumab, 2.52 CI = 1.78-3.57 and bevacizumab, 1.97 CI = 1.43-2.71.
Conclusions: For first line treatment, sunitinib was the most effective TCT in relation to 
FPS; there was no alteration of TS and RR was small but significant for sunitinib and 
bevacizumab. Available studies could not conclude any results for second line treatments.
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INtRODUctION
The best treatment for renal tumor is sur-
gery, especially when the tumor is located in the 
kidney with no lymph node involvement or me-
tastasis. In advanced renal cell carcinoma (ARCC), 
being the tumor incurable, most available treat-
ments are palliative and the patients usually die. 
In those cases, the objective is to increase total 
survival (TS), free survival progression (FSP), res-
ponse rate (RR) and quality of life (QF) of patients.
Before target cell therapies (TCT) became 
available, interleucin-2 (IL2) and interferon-alpha 
(IFN-α) were the main used therapies for this dise-
ase, with low response, from 5% to 20% (1-4). At 
present, TCT include sorafenib, sunitinib, bevaci-
zumab, temsirolimus and everolimus.
 Sorafenib and sunitinib are oral inhibitors 
of tirosine-kinases. Sorafenib inhibits endothelial 
growth receptors (VEGF) and platelet-derived gro-
wth factors (PDGF). Sunitinib inhibits VEGF 1, 2 
and 3 with antitumor and anticoagulant effects.
Bevacizumab is a recombinant huma-
nized monoclonal antibody that combines to a 
VEGF and inhibits its biological activity. It is 
used intravenously.
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Temsirolimus is an inhibitor of rapamicin-
-kinase (mTOR) with antiangiogenic effect, as well 
as everolimus. Everolimus is used orally.
MAtERIAl AND MEtHODS
Systematic review (SR) was made by se-
arch of clinical randomized trials (CRT) that used 
TCT to treat ARCC compared to IFN-α as first and 
second lines of treatment.
The search was made at the databases EM-
BASE, LILACS, MEDLINE, The Cochrane Control-
led Trials Register, Cochrane Database of Systema-
tic Reviews and Cochrane Clinical Trials.
 Other sources included American Society 
of Clinical Oncology, European Society of Medical 
Oncology, Brazilian Society of Clinical Oncolo-
gy, Cancer Brazilian Society, American Society of 
Urology and Brazilian Urological Society.
The following key words were used for the 
search:
(“Kidney Neoplasms” [Mesh] OR kidney 
cancer OR renal carcinoma) AND (“Randomized 
Controlled Trial” [Publication Type] OR random* 
OR single blind OR double blind “First Line The-
rapy and Renal Cancer”) AND (“First Line Thera-
py and Renal Cancer and Randomized Controlled 
Trials” [Mesh]) AND (“Second Line Therapy and 
Renal Cancer and Randomized”) [MESH].
The selected studies were realized from Ja-
nuary 2000 to December 2011, in English, Spanish 
or Portuguese.
The obtained summaries were evaluated 
by two independent reviewers and those who ful-
filled the select criteria were pre-selected. When 
both reviewers disagreed, the article(s) was (re) re-
viewed by a third reviewer.
The inclusion criteria were: multicentric 
randomized double-blind studies that compared 
TCT with IFN-α. All studies that did not meet tho-
se criteria were excluded and those in duplicity 
were considered only one time.
The studies were identified by the reviewers 
by the first author’s name and year of publishing. 
All data were directly obtained from the studies 
or calculated based on the available information: 
epidemiological data, methods and results, inclu-
ding FSP, TS and RR. Bias methodological aspects 
(5) were also analyzed, including   randomization 
methods, double-blind aspects, intention of treat-
ment, loss of patients, sample size, multicentricity 
and study sponsors. 
Statistic analysis was based on the null 
hypothesis that TCT does not change the results 
of the treatment. It was used the software Review 
Manager 5.1 (Cochrane Collaboration Software) 
(6). In the hypothesis test the level of significance 
was α = 0.05 for the rejection of the null hypothe-
sis, in a two-tailed test. 
MEtA-ANAlYSIS
Meta-analysis of the quantitative variables 
related to TS, FSP and RR were done by Relative 
Risk (RRi) (6).
HEtEROGENEItY ANAlYSIS
In the present study we used the hetero-
geneity index I2 based on the chi-square test cal-
culus (7). When it was observed heterogeneity at 
meta-analysis with I2 > 70% the reason was rese-
arched (5) using new analysis excluding discre-
pant studies in order to obtain new heterogeneity 
indexes (5).
RESUltS
Systematic Review
After the search using the selected key wor-
ds and databases, 148.805 studies were initially se-
lected, related to renal cancer. In order to select 
those randomized studies that used TCT, new key 
words were applied and it was obtained 375 refe-
rences. Among these, after analysis of the sum-
mary, 33 were selected to detailed analysis of the 
complete article and 21 were excluded (Figure-1).
Thirteen studies were included for syste-
matic revision analysis, divided by: first line tre-
atment: Cella et al., 2008 (8); Escudier et al., 2007 
(9), 2009 (10); 2010 (11); Hudes et al., 2007 (12); 
Motzer et al., 2007 (13), 2009 (14); Rini et al., 
2008 (15); Rini et al., 2010 (16); Yang et al., 2010 
(17) and second line treatment: Escudier et al., 
2007 (18); Motzer et al., 2008 (19) and Bukowski 
et al., 2007 (20).
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Figure 1 - Search result: systematic review.
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Most patients of those studies, although 
with different selection criteria, had the following 
characteristics: age greater than 18 years old, me-
tastatic renal clear-cells tumor, no previous syste-
mic therapy, good medullar response, good hepa-
tic and renal function, good condition, ECOG (0-1) 
or Karnofsky ≥ 60 or 70%. Patients with metasta-
sis, radicular compression, uncontrolled systemic 
hypertension, pregnancy and uncontrolled thyroid 
diseases were not included.
Quality of the Studies
The evaluated studies were heterogeneous 
and most were sponsored by the laboratories ma-
nufacturers. Most were randomized studies, dou-
ble-blind and multicentric. The studies were clas-
sified as originals or complementary: the originals 
are initial studies of analysis of first publication 
(interim analysis) and the complementary when 
final analysis was described in a posterior publi-
cation (Table-1).
MEtA-ANAlYSIS
Not all selected studies were evaluated at 
meta-analysis due to the selected end points. Only 
seven articles of first line treatment and two of se-
cond line were evaluated.
Free Survival Progression (FSP)
Regarding FSP, meta-analysis used 1375 
treated patients with target cell therapies (first line 
treatment) versus 1353 treated patients with inter-
feron-alpha (control group). Among these patients, 
628 progressed in group TCT and 746 in control 
group (Figure-2).
Meta-analysis showed RRi of 0.83, IC=0.78-
0.87, I2= 94% and p < 0.00001, and the best parame-
ters were observed of the sunitinib study with RRi of 
0.38, CI = 0.25-0.58 (Motzer et al., 2007 (13)), follo-
wed by the bevacizumab study with RRi of 0.62, 
CI = 0.47-0.83 (Escudier et al., 2007 (9)) and tem-
sirolimus, RRi of 0.78 CI = 0.70-0.87 (Hudes et al., 
2007 (12)). Worse results were from the study with 
bevacizumab, with RRi of 0.97, CI = 0.92-1.02 (Rini 
et al., 2010 (16)) and the study of sorafenib, with RRi 
of 0.96 CI = 0.83-1.11 (Escudier et al., 2009(10)).
Total Survival
Four studies evaluated TS. Rini 2010 (16) 
did not inform how many patients survived or died 
in each arm, and the study was excluded at final 
table 1 - Metodological characteristics of the included studies.
Author Year N randomized Multicentric Double blind Line of treatment Study analysis
Escudier et al. (18) 2007 903 NC Y Y 2nd O
Escudier et al. (9) 2007 649 A Y Y 1st O
Escudier et al. (11) 2010 649 A Y Y 1st C
Motzer et al. (19) 2008 410 A Y Y 2nd O
Hudes et al. (12) 2007 626 A Y NC 1st O
Yang et al. (17) 2010 626 A Y Y 1st C
Escudier et al. (10) 2009 189 A Y NC 1st O
Rini et al. (15) 2008 732 A Y N 1st O
Rini et al. (16) 2010 732 A Y N 1st C
Motzer et al. (13) 2007 750 A Y N 1st O
Motzer et al. (14) 2009 750 A Y N 1st C
Cella et al. (8) 2008 750 A Y N 1st C
A - Acceptable; Y - Yes N - No; O - Original study; c - Complementar study; Nc – not clear
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Figure 2 - Meta-analysis of free survival progression.
analysis. Among the considered studies, it was eva-
luated TS of 1007 patients treated with TCT and 
990 with interferon-alpha, and 422 and 443 died 
respectively (Figure-3).
 Meta-analysis RRi of TS was 0.94, CI = 
0.86-1.02, I2 of 0% and p = 0.14. The values of 
RRi of each study were: sorafenib: RRi 0.63 CI = 
0.23-1.71 (Escudier et al., 2009 (10)), bevacizumab: 
RRi 0.95 CI = 0.86-1.06 (Escudier et al., 2007 (9)), 
sunitinib: RRi 0.95 CI = 0.83-1.09 (Motzer et al., 
2007 (13)) and temsirolimus: RRi 0.59 CI = 0.22-
1.61 (Hudes et al., 2007 (12)).
Respost Rate
RR was analyzed in 1375 patients treated 
with TCT and 1353 patients with interferon-alpha. 
Among these patients, 384 and 141 showed com-
plete response respectively (Figure-4).
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 RRi obtained using meta-analysis of the 
studies was 2.68 CI = 2.25-3.20, I2 68% and p < 
0.00001. Best RR result was obtained with suniti-
nib (Motzer et al., 2007 (13)) with RRi of 3,83 and 
CI = 2.86-5.12. Following, according to favorable 
responses: bevacizumab, RRi 2.52 CI = 1.78-3.57 
(Escudier et al., 2007 (9)), bevacizumab, RRi 1.97 
CI = 1.43-2.71 (Rini et al., 2010 (16)), temsirolimus, 
RRi 1.78 CI = 0.84-3.77 (Hudes, et al., 2007 (12)) 
and finally sorafenib, RRi 0.32 CI = 0.01-7.62 (Es-
cudier et al., 2009 (10)).
Heterogeneity (I2)
Due to the high level of I2 = 94% at meta-
-analysis of FPS and of I2 = 68% at objective RR, 
several analysis were made excluding each work 
of the respective meta-analysis. TS meta-analysis 
showed I² = 0%, so the analysis of heterogeneity 
was unnecessary.
 During FSP analysis the maximum value 
obtained for heterogeneity was observed when the 
study of Rini et al (2010 (16) was excluded: I2 = 89%, 
showing great heterogeneity among the studies. Af-
ter excluding the study of Motzer et al., 2007 (13) 
during RR analysis heterogeneity value was I2 = 0%.
Second line studies
It was not possible to perform meta-analy-
sis, since populations of both studies were qui-
te different. One of the studies included patients 
Figure 3 - Meta-analysis of total Survival.
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Figure 4 - Meta-analysis of Response Rate.
previously treated with systemic therapy and the 
other patients treated previously with sunitinib, 
sorafenib or both (Escudier et al., 2007 (18) and 
Motzer et al., 2008 (19), respectively).
SURVIVAl cURVES
FSP curves of first line treatments showed 
little improvement, in order of importance, with 
the use of sunitinib, bevacizumab and interferon-
-alpha. TS curves were very similar and with no 
statistical differences (Figure-5).
In relation to first line treatments of high 
risk patients, FSP and TS curves showed a little 
better improvement with temsirolimus, compared 
to interferon-alpha (Figure-6).
TS curves of second line treatment were 
very similar and with no significant difference, 
while FSP curves showed some advantages, in 
order of importance, with the use of everolimus, 
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Figure 5 - Free survival progression and total survival curves for first line treatment.
Figure 6 - Free survival progression and total survival curves for first line treatment of high risk patients.
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sorafenib and finally only palliative care (BSC) 
(Figure-7). As previously related, second line tre-
atments were very heterogeneous and it was not 
possible to perform meta-analysis.
DIScUSSION
The lack of suitable studies that evaluate 
efficiency of target cell therapies (TCT) for advan-
ced renal cell carcinoma (ARCC) was noted during 
systematic review and only a few were submitted 
to meta-analysis: seven first line treatments and 
two second line treatments.
It was also observed difficulty to collect 
data from the studies, since some presented not 
clear and non-objective results. Among the revised 
studies, there were several difficulties regarding 
interpretation of results, such as randomization, 
quantification of response rate, number of deaths 
during the study, that impaired TS calculus.
Many selected works were excluded sin-
ce they were not prospective and with a control 
group, randomized and with the necessary infor-
mation for analysis. Subgroup analysis studies 
were also excluded as well as those with duplica-
ted populations.
At present, there are several available 
treatments with TCT, as well as with pazopanib 
(21,22), axitinib (23) and tivozamib (24). However, 
only studies that used sorafenib, sunitinib, beva-
cizumab, temsirolimus and everolimus were inclu-
ded for comparision with interferon-alpha.
 Meta-analysis of FSP showed RRi with a 
slight favoring for the treatment with TCT compa-
red to control group treated with IFN-α (RRi 0,83 
CI = 0.78 - 0.87). However, two aspects must be 
pointed out. First, better result of RRi sunitinib (RR 
0.38 CI = 0.25 - 0.58 (13)) compared to other dru-
gs, showing better efficacy of this drug as first line 
treatment. Second, bevacizumab studies showed 
Figure 7 - Free survival progression and total survival curves for second line treatment.
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different and controvertial results (Escudier et al., 
2007 (9) and Rini et al., 2010 (16)), with different 
Rris and CIs: RR 0.62 CI = 0.47 - 0.83 and RR 0.97 
CI = 0.92 - 1.02, respectively.
RRi values of TS of the sorafenib studies 
(Escudier et al., 2009 (11)), bevacizumab (Escudier 
et al., 2007 (9)), sunitinib (Motzer et al., 2007 (13)) 
and temsirolimus (Hudes et al., 2007 (12)) did not 
indicate significant differences of TS RRi of patients 
of control group, confirmed by the value of I² = 0.
In relation to RR meta-analysis, treat-
ment with sunitinib was superior (RR 3.83 and CI 
[2.86-5.12]), compared to other drugs. This diffe-
rence was so bigger that, when the heterogeneous 
analysis was performed, the initial I² was 68% and 
became 0% after the exclusion of that paper (Mot-
zer et al., 2007 (13)).
All simulations of heterogeneity analysis 
of FSP showed high I² (> 50%) demonstrating that 
the five first line treatment studies are not homo-
geneous. The differences may be related to varied 
results of efficiency of the four drugs, population 
characteristics and methodologies. It was not pos-
sible to prove that the five studies presented ho-
mogeneously results of FSP. In the future, further 
studies are necessary with a bigger and more ho-
mogeneous population.
cONclUSIONS
 For first line treatment, sunitinib is the 
most efficient therapy regarding FSP; the studies 
did not show any improvement of TS and RR was 
low, but significant, using sunitinib and bevaci-
zumab. Available studies could not conclude the 
use as second line therapies. Those results must 
be carefully analyzed due to the small number of 
available studies.
cONFlIct OF INtERESt
None declared.
REFERENcES
1. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update 
for high-dose recombinant interleukin-2 in patients with renal 
cell carcinoma. Cancer J Sci Am. 2000; 6(Suppl 1): S55-7.
2. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, 
Logan TF, et al.: Randomized phase III trial of high-dose 
interleukin-2 versus subcutaneous interleukin-2 and inter-
feron in patients withmetastatic renal cell carcinoma. J Clin 
Oncol. 2005; 23: 133-41. Erratum in: J Clin Oncol. 2005; 
23: 2877.
3. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, 
Mariani T, et al.: Phase III trial of interferon alfa-2a with 
or without 13-cis-retinoic acid for patients with advanced 
renal cell carcinoma. J Clin Oncol. 2000; 18: 2972-80.
4. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartz-
entruber DJ, Hwu P, et al.: Randomized study of high-dose 
and low-dose interleukin-2 in patients with metastatic renal 
cancer. J Clin Oncol. 2003; 21: 3127-32.
5. Higgins JPT, Green S. Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.0.2 [updated Septem-
ber 2009]: The Cochrane Collaboration; 2008. Available at: 
www.cochrane-handbook.org
6. The Nordic Cochrane Centre. Review Manager (RevMan) 
[Computer program]. Version 5.0. Copenhagen: The Co-
chrane Collaboration; 2008. Available at: http://ims.co-
chrane.org/home
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measur-
ing inconsistency in meta-analyses. BMJ. 2003; 327: 557-
60.
8. Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau 
C, Kim ST, et al.: Quality of life in patients with metastatic 
renal cell carcinoma treated with sunitinib or interferon 
alfa: results from a phase III randomized trial. J Clin Oncol. 
2008; 26: 3763-9.
9. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda 
S, Szczylik C, et al.: Bevacizumab plus interferon alfa-2a for 
treatment of metastatic renal cell carcinoma: a randomised, 
double-blind phase III trial. Lancet. 2007; 370: 2103-11.
10. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, 
Rolland F, et al.: Randomized phase II trial of first-line treat-
ment with sorafenib versus interferon Alfa-2a in patients 
with metastatic renal cell carcinoma. J Clin Oncol. 2009; 
27: 1280-9. Erratum in: J Clin Oncol. 2009; 27: 2305.
11. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, 
Bracarda S, et al.: Phase III trial of bevacizumab plus in-
terferon alfa-2a in patients with metastatic renal cell car-
cinoma (AVOREN): final analysisof overall survival. J Clin 
Oncol. 2010; 28: 2144-50.
12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Ka-
poor A, et al.: Temsirolimus, interferon alfa, or both for 
advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 
2271-81.
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bu-
kowski RM, Rixe O, et al.: Sunitinib versus interferon alfa 
in metastatic renal-cell carcinoma. N Engl J Med. 2007; 
356: 115-24.
IBJU | Meta-analysis of target terapies for the treatMent of Metastatic renal cancer
778
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bu-
kowski RM, Oudard S, et al.: Overall survival and updated 
results for sunitinib compared with interferon alfa in pa-
tients with metastatic renal cellcarcinoma. J Clin Oncol. 
2009; 27: 3584-90.
15. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou 
SS, et al.: Bevacizumab plus interferon alfa compared with 
interferon alfa monotherapy in patients with metastatic renal 
cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-8.
16. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, 
Archer L, et al.: Phase III trial of bevacizumab plus inter-
feron alfa versus interferon alfa monotherapy in patients 
with metastatic renal cellcarcinoma: final results of CALGB 
90206. J Clin Oncol. 2010; 28: 2137-43.
17. Yang S, de Souza P, Alemao E, Purvis J: Quality of life in 
patients with advanced renal cell carcinoma treated with 
temsirolimus or interferon-alpha. Br J Cancer. 2010; 102: 
1456-60.
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, 
Siebels M, et al.: Sorafenib in advanced clear-cell renal-cell 
carcinoma. N Engl J Med. 2007; 356: 125-34. Erratum in: N 
Engl J Med. 2007; 357: 203.
19. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bra-
carda S, et al.: Efficacy of everolimus in advanced renal cell 
carcinoma: a double-blind, randomised, placebo-controlled 
phase III trial. Lancet. 2008; 372: 449-56.
20. Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TAR-
GETs Clinical Trial Group. Effects of sorafenib on symp-
toms and quality of life: results from a large randomized 
placebo-controlled study in renalcancer. Am J Clin Oncol. 
2007; 30: 220-7.
21. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wag-
staff J, et al.: Pazopanib in locally advanced or metastatic 
renal cell carcinoma: results of a randomized phase III trial. 
J Clin Oncol. 2010; 28: 1061-8.
22. Rexer H: First-line therapy of advanced or metastasized re-
nal cell cancer: open randomized phase III sequence study 
to examine the effectiveness and tolerance of sorafenib 
followed by pazopanib versus pazopanib followed by 
sorafenib in the first-line treatment of patients with ad-
vanced or metastasized renal cell cancer (SWITCH-2 - AN 
33/11)]. Urologe A. 2012; 51: 724-6.
23. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hut-
son TE, et al.: Comparative effectiveness of axitinib versus 
sorafenib in advanced renal cell carcinoma (AXIS): a ran-
domised phase 3 trial. Lancet. 2011; 378: 1931-9. Erratum 
in: Lancet. 2012; 380: 1818.
24. Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischen-
ko AA, Chacko RT, et al.: Antitumor activity and safety of 
tivozanib (AV-951) in a phase II randomized discontinua-
tion trial in patients with renal cellcarcinoma. J Clin Oncol. 
2012; 30: 1678-85.
______________________
Correspondence address:
Marcela Andrea Durán Haun Seneatore, MD
Rua Luverci Pereira de Souza, 210
Campinas, São Paulo, Brasil
Telephone: + 55 19 3289-1838
E-mail: marceladuranduran@gmail.com
